Estrella Immunopharma, Inc. (NASDAQ:ESLA) Sees Significant Drop in Short Interest

Estrella Immunopharma, Inc. (NASDAQ:ESLA) saw a large decline in short interest during the month of May. As of May 15th, there was short interest totaling 94,135 shares, a decline of 36.2% from the April 30th total of 147,543 shares. Approximately 0.5% of the company’s stock are short sold. Based on an average daily volume of 35,197 shares, the short-interest ratio is currently 2.7 days.

Estrella Immunopharma Price Performance

NASDAQ:ESLA opened at $1.08 on Wednesday. Estrella Immunopharma has a 12-month low of $0.78 and a 12-month high of $3.15. The firm has a market capitalization of $46.47 million, a P/E ratio of -3.18 and a beta of 0.85. The business has a 50 day simple moving average of $1.35 and a 200 day simple moving average of $1.39.

Estrella Immunopharma (NASDAQ:ESLA) last announced its quarterly earnings results on Friday, May 15th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.03. Research analysts anticipate that Estrella Immunopharma will post -0.39 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. Marshall Wace LLP acquired a new position in Estrella Immunopharma during the 4th quarter worth $88,000. Geode Capital Management LLC lifted its holdings in shares of Estrella Immunopharma by 8.2% in the fourth quarter. Geode Capital Management LLC now owns 109,808 shares of the company’s stock valued at $171,000 after buying an additional 8,318 shares during the period. Quadrature Capital Ltd acquired a new stake in shares of Estrella Immunopharma in the fourth quarter valued at $43,000. Renaissance Technologies LLC lifted its holdings in shares of Estrella Immunopharma by 1,045.7% in the fourth quarter. Renaissance Technologies LLC now owns 122,468 shares of the company’s stock valued at $191,000 after buying an additional 111,779 shares during the period. Finally, XTX Topco Ltd lifted its holdings in shares of Estrella Immunopharma by 376.9% in the fourth quarter. XTX Topco Ltd now owns 49,472 shares of the company’s stock valued at $77,000 after buying an additional 39,099 shares during the period. Institutional investors and hedge funds own 0.35% of the company’s stock.

Analysts Set New Price Targets

ESLA has been the subject of several research analyst reports. Weiss Ratings downgraded shares of Estrella Immunopharma from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, May 28th. D. Boral Capital reiterated a “buy” rating and issued a $8.00 price target on shares of Estrella Immunopharma in a report on Monday, February 9th. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $8.00.

Estrella Immunopharma Company Profile

Estrella Immunopharma, Inc, a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103.